weight loss with glp-1 agonists Rx Trends: Real-World Data on GLP-1s for Glucagon-like peptide-1 receptor agonists and
Description
& Lund, E
[3] Gallbladder disease: A 2022 review found that semaglutide use was associated with a higher risk of gallstones and cholecystitis, especially during rapid weight loss phases, similar to the weight loss rates typical of Ozempic users
A 2020 study found that, compared to a placebo, people taking B
Utility of glucagon-like peptide 1 receptor agonists as anti-obesity medications in liver transplant recipients
